QS

Products

As a model of the industry, Quinovare has ISO 13458 and CE Mark certificate in 2017 and has always been positioned as a benchmark for needle-free injector and is constantly leading the definition of new standards for needle-free injection device. Quinovare, adhering to the principle of care, patience and sincerity, maintaining high quality of each injector. We hope needle-free injection technology benefit more patient and improves the quality of patient’s life by reducing injection pain. Quinovare strives tirelessly to realize the vision “A better world with needle-free diagnosis and therapy”.

As a model of the industry, Quinovare has ISO 13458 and CE Mark certificate in 2017 and has always been positioned as a benchmark for needle-free injector and is constantly leading the definition of new standards for needle-free injection device. Quinovare, adhering to the principle of care, patience and sincerity, maintaining high quality of each injector. We hope needle-free injection technology benefit more patient and improves the quality of patient’s life by reducing injection pain. Quinovare strives tirelessly to realize the vision “A better world with needle-free diagnosis and therapy”.

QS

Feature Products

A better world with needle-free diagnosis and therapy

QS

About us

Quinovare is a high-tech enterprise focusing on the research and development, production and sales of needle-free injector and its consumables in various field with 100,000-degree sterile production workshops and 10,000-degree sterile laboratory. We also have a self-designed automated production line and use top class machinery. Each year we produces 150,000 pieces of injector and up to 15 million pieces of consumables.

  • news
  • news
  • news

QS

Clinical Trials

  • Lispro administered by the QS-M Needle-Free Jet Injector generates an earlier insulin exposure

    - Published in Expert Opinion Lispro administered by QS-M needle-free injector results in earlier and higher insulin exposure than conventional pen, and a greater early glucose-lowering effect with similar overall potency. ...

  • Comparison of jet injector and insulin pen in controlling plasma glucose and insulin concentrations in type 2 diabetic patients

    - Published in Medicine Postprandial plasma glucose excursions at the time points of 0.5 to 3 hours were obviously lower in the jet-treated patients than the pen-treated ones (P<0.05). Postprandial plasma insulin levels were markedly higher in the jet-treated patients than the pen-t...

  • A prospective, multicenter, randomized, open-label, parallel-group Clinical Trial comparing Patient satisfaction and compliance with a Needle-free Insulin Injector versus conventional insulin pen i...

    - Published in Lancet There was no new indurations observed in NIF group compared with IP.(P=0.0150) Broken needle were observed in the IP group, no risk in NIF group. The adjusted mean reduction from baseline of HbA1c 0.55% at week 16 in NFI group was non-inferior and statistically super...